Bowel disease (IBD)
View of Inflammatory Bowel Disease: An interview with Dr. John Marshall
... matory Bowel Disease ...Irritable Bowel Syndrome, particularly post-infectious Irritable Bowel Syndrome, but also more recently related to ...
4
Common variants at five new loci associated with early-onset inflammatory bowel disease.
... inflammatory bowel disease Marcin Imielinski 1,28 , Robert N Baldassano 2,3,28 , Anne Griffiths 4,28 , Richard K Russell 5,28 , Vito Annese 6,28 , Maria Dubinsky 7,28 , Subra Kugathasan 8,28 , Jonathan P ...
13
Discrimination between inflammatory bowel disease (IBD) phenotypes by GC×GC-HRTOFMS
... DISCRIMINATION BETWEEN INFLAMMATORY BOWEL DISEASE (IBD) PHENOTYPES BY GC×GC-HRTOFMS Nicolas J. Di Giovanni 1 , M-A Meuwis 2 , E Louis 2 , J-F Focant 1 1 MS Laboratory Organic and Biological Analytical ...
1
Ecological Structuring of Temperate Bacteriophages in the Inflammatory Bowel Disease-Affected Gut
... * Correspondence: ogata@kuicr.kyoto-u.ac.jp; Tel.: +81-774-38-3270 Received: 30 September 2020; Accepted: 23 October 2020; Published: 27 October 2020 Abstract: The aim of this study was to elucidate ...
16
Complementary and alternative medicine in inflammatory bowel disease
... ence in in flammatory bowel disease (IBD). 1 Over the past decade, the use of CAM has received increasing attention as reflected by the dramatic increase in the number of articles identified on MED- LINE using ...
2
Association mapping of inflammatory bowel disease loci to single variant resolution.
... 39. Roadmap Epigenomics Consortium et al. Integrative analysis of 111 reference human epigenomes. Nature 518, 317–330 (2015). Supplementary Information is available in the online version of the paper. Acknowledgements We ...
19
Effectiveness Research in Inflammatory Bowel Disease: A Necessity and a Methodological Challenge
... Efficacy, safety and economic issues are the main factors influencing the use of inflammatory bowel disease [IBD]-related medications. The best level of evidence comes from randomised clinical trials. The ...
8
Brain-gut interactions in inflammatory bowel disease.
... inactive disease (90-94). Regardless of disease type, individuals with increased disease activity were more likely to report increased anxiety and depression while individuals with decreased ...
53
Fecal microbiota transplantation in inflammatory bowel disease: the quest for the holy grail
... Introduction Although major progress has been achieved in recent years, the pathogenesis of Inflammatory Bowel Disease (IBD) has not yet been fully elucidated. It is generally accepted that IBD is caused ...
20
Management of patients with inflammatory bowel disease and spondyloarthritis
... Inflammatory Bowel Disease) consensus defined mucosal healing in combination with resolution of symptoms as one of the major treatment goals for patients with IBD 41 ...and disease-modifying studies ...
46
Singular manifolds of proteomic drivers to model the evolution of inflammatory bowel disease status
... Inflammatory bowel disease (IBD). IBD is an intestinal disease of unknown cause whose prevalence is in continuous growth at ...Crohn’s disease (CD) and ulcerative colitis (UC) are the main ...
13
View of Management of Patients with Inflammatory Bowel Disease Hospitalized in Intensive Care Unit
... inflammatory bowel disease (IBD) [Crohn ’s disease and ulcerative colitis] are more likely to be hospitalized in intensive care unit because of their immunosuppressive and/or biologic therapy ...
8
Plasmacytoid Dendritic Cells Are Largely Dispensable for the Pathogenesis of Experimental Inflammatory Bowel Disease
... Inflammatory bowel disease (IBD) is a chronic inflammatory condition caused by an aberrant immune response to microbial components of the gastrointestinal ...the disease remains ...
17
Expression of HLA-G in inflammatory bowel disease provides a potential way to distinguish between ulcerative colitis and Crohn's disease.
... Crohn's disease, HLA-G, in¯ammatory bowel disease, ulcerative colitis Abstract In addition to being involved in nutrient uptake, the epithelial mucosa constitute the ®rst line of defense against ...
6
Tailoring Biologic or Immunomodulator Treatment Withdrawal in Inflammatory Bowel Disease.
... Edouard Louis* Department of Gastroenterology, University and CHU Liège, Liège, Belgium There is currently no cure for inflammatory bowel disease. Most recent treatments and treatment strategies allow for ...
6
Review article: withdrawal of 5-aminosalicylates in inflammatory bowel disease.
... “inflammatory bowel disease”, “Ulcerative Colitis” and “Crohn's Disease” with the subheadings “5-ASA with- drawal”, “5-ASA de-escalation”, “risk of relapse”, “cost saving” and “colorectal ...
12
Characterization of Human Colon Organoids From Inflammatory Bowel Disease Patients
... doi: 10.3389/fcell.2020.00363 Edited by: Océane C. B. Martin, Université de Bordeaux, France Reviewed by: John Charles Rotondo, University of Ferrara, Italy Martha Ruskin Stampfer, Lawrence Berkeley National Laboratory, ...
14
Upregulation of enteric alpha-synuclein as a possible link between inflammatory bowel disease and Parkinson's disease
... With interest, we read the review by Lee et al on the possible link between inflammatory1 bowel disease and Parkin- o ’ . Af g c c o g fl mm o o l k o ’ p m olog c ll g c ll linked, the authors discuss the ...
4
[Immunopathogenesis of inflammatory bowel disease.]
... 6 Moehle C, Ackermann N, Langmann T, Aslanidis C, Kel A, Kel-Margoulis O, et al. Aberrant intestinal expression and allelic variants of mucin genes associated with inflammatory bowel disease. J Mol Med ...
13
Strategic use of immunosuppressants and anti-TNF in inflammatory bowel disease.
... Edouard Louis Department of Gastroenterology, University Hospital CHU of Liège, Liège , Belgium ti-TNF? The main justification of immunosuppressant mono- therapy is the low cost of this treatment and the possibility of ...
6